NRP1 and neoplasm: Results showed that intra-tumoural (i.t.)administration of anti-Nrp-1 mAb, or intra-peritoneal (i.p.)injection of anti-PD-1 mAb, inhibited tumour growth as compared with control treatment (Fig. 6a, b, Supplementary Table 2).